INTRODUCTION {#s1}
============

Metastatic disease accounts for more than 90% of deaths in patients with solid tumors \[[@R1]\]. Metastasis is a complex process requiring tumor cells to invade into the surrounding tissue, gain access to vasculature, survive transport, exit the vasculature and then resume growth in a foreign tissue environment \[[@R2]\]. Our understanding of metastasis has been greatly improved by the recognition that cancer cells can acquire the ability to accomplish several steps of the metastatic process at once through the engagement of a latent cellular program, the Epithelial-Mesenchymal Transition (EMT) \[[@R3],[@R4]\]. EMT plays an important role in controlling critical morphogenetic steps during normal embryonic developmental processes, and has been linked to the acquisition of cancer cell motility and invasiveness in solid malignancies. During both normal development and tumor progression, EMT is orchestrated by a set of pleiotropically acting transcription factors (TFs), such as Twist, Snail, Slug, ZEB1/2 that together form an intricate transcriptional circuitry \[[@R5]--[@R7]\]. Through the action of EMT-TFs, which mainly act as transcriptional repressors, cells lose epithelial traits, such as expression of E-cadherin and ZO-1, leading to the dissolution of adherens and tight junctions (Figure [1](#F1){ref-type="fig"}). Repression of epithelial markers is paralleled by transcriptional upregulation of mesenchymal adhesion molecules, such as N-cadherin and fibronectin and matrix degrading enzymes, respectively. Together, these changes enable epithelial cells to switch from an apical-basal polarity and restricted lateral, collective movement confined by the basement membrane to a front-to-back polarity with the ability to freely migrate and invade as single cells. Thus, in embryonic development, EMT is critical for mesoderm formation during gastrulation. Overall, EMT affects cellular distribution throughout the embryo during processes such as gastrulation and neural crest migration. Over the last few years EMT has emerged as a key process employed by cancer cells to accomplish the early steps of the metastatic process, including local tissue invasion, entry into blood and/or lymphatic vessels, survival during transit and exit from the circulation into distant tissue parenchyma.

![The process of EMT and its reversible MET\
Epithelial cells having a particular set of markers undergo biochemical changes and acquire different set of markers for a mesenchymal phenotype. ZO-1, zona occludens; MUC1, mucin 1; FOXC2, forkhead box C2.](oncotarget-05-2016-g001){#F1}

Activation of an EMT program is also coupled with the ability of cancer cells to initiate experimental tumors in mice with high efficiency, although the exact molecular mechanisms linking EMT and tumor-initiating capacity of cancer cells still remain to be determined \[[@R8],[@R9]\]. Given the similarity of experimental tumor initiation and establishment of macroscopic metastases, it is conceivable that EMT is involved in both the early and late steps of the metastatic cascade, which encompass outgrowth of disseminated tumor cells. Intriguingly, recent research points to the necessity of the reversal of EMT by means of a Mesenchymal-Epithelial Transition (MET) at the metastatic site to enable the outgrowth of disseminated tumor cells (DTC) into macroscopic metastases \[[@R10]\], supported by earlier work pointing to the importance of MET in the metastatic cascade \[[@R11]\]. These experimental studies are supported by the clinico-pathological observation that most metastases arising from carcinomas display an epithelial phenotype mimicking the differentiation patterns found in the cognate primary tumor site of a given tumor \[[@R12]\]. However, these seemingly opposing observations may be reconciled by comprehending EMT as a highly dynamic and reversible process. In this scenario, the most aggressive tumor cells would be predicted to be those displaying a high degree of cellular plasticity or a mixed phenotype integrating epithelial and mesenchymal characteristics. This model is supported by recent observations of dynamic changes in epithelial and mesenchymal features in circulating tumor cells of breast cancer patients \[[@R13]\]. Together, these data suggest that inhibition of epithelial plasticity is an attractive approach for therapeutic intervention aimed at inhibiting cell-state transitions, rather than targeting mutated or otherwise genetically altered gene products. However, the precise molecular links between EMT programs and cellular plasticity are just beginning to be unraveled.

Considering the dynamic and drastic transcriptional changes that occur during both EMT and MET, broad sweeping, reversible changes in epigenetic modifications which affect chromatin state, represent a central and crucial regulatory component of the metastatic process. Changes in gene expression do not depend solely upon the availability of appropriate transcription factors, but also upon the degree of "openness" or "closedness" of the chromatin since both the binding of a TF to DNA as well as its ability to recruit additional transcriptional co-regulatory proteins depends upon changes in histone modifications at the target gene. In this regard, emerging data have shown that EMT also involves epigenetic reprogramming with widespread alterations to chromatin modifications at both the DNA and protein level. For example, EMT-TFs, such as Twist, Snail, Slug, ZEB1 and ZEB2 recruit various histone-modifying complexes to chromatin, thereby mediating epigenetic silencing of genes \[[@R14]\]. Here, we review the interplay between EMT-TFs, transcriptional regulation of EMT markers and chromatin modifiers. Emphasis is laid primarily on histone modifications largely due to their amenability to intervention in possible future therapies to prevent metastasis or metastatic relapse.

Epigenetic Control {#s1_1}
------------------

Epigenetic regulation of gene expression occurs largely through reversible chemical modification of DNA or histone proteins, which do not alter the DNA sequence, but instead control its accessibility and/or ability to be read \[[@R15]\]. Certain epigenetic modifications are almost exclusively associated with constitutively silenced regions of the genome ("heterochromatin") while other modifications are almost exclusively found in actively transcribed regions of the genome ("euchromatin") \[[@R16]\]. Other epigenetic changes in chromatin structure can occur through the exchange of variant histones or assembly and disassembly of chromatin structure via histone chaperones, or through ATP-dependent chromatin remodeling, for example, by members of the Swi/Snf family of proteins \[[@R17],[@R18]\]. Substantial changes in epigenetic modifications occur to different degrees during various developmental processes such as germ cell development and stem cell differentiation \[[@R19]\], as well as during pathologic processes such as tumorigenesis \[[@R20]\]. Chromatin is composed of DNA wrapped around a nucleosome containing two of each of the core histones H2A, H2B, H3 and H4. Each of the core histone proteins can be modified at the post-translational level in various ways including the acetylation, methylation, ubiquitination and sumoylation of the amino terminus of lysine side chains; methylation or citrullination of arginine residues; as well as phosphorylation of serine, threonine and tyrosine residues \[[@R21],[@R22]\]. The specific combination of histone modifications, commonly referred to as the "histone code", is thought to determine the functional outcome, probably largely due to the recruitment of scaffolding proteins such as bromo- and chromodomain proteins which specifically recognize acetylated and methylated lysine residues, respectively \[[@R21],[@R23]\]. A major emphasis has been placed on understanding the role of DNA methylation in cancer, but more studies are beginning to determine the roles of various histone modifications, their modifying enzymes and overall chromatin structure in controlling tumor progression and metastasis. This has been fueled at least in part by the recent discovery that epigenetic regulatory proteins are the frequent targets of genetic mutation in many types of hematological malignancies and solid tumors \[[@R24]\]. However, the role of most of these mutations in EMT or metastasis remains unknown.

Several signaling networks including hypoxia, TGFβ, Wnt and Notch signaling may all activate EMT by wide-spread transcriptional changes via the activation of specific transcription factors \[[@R25]\] which elicit their effects on gene transcription and the epigenetic landscape by recruiting epigenetic regulatory proteins to specific genes, including those associated with an epithelial or mesenchymal phenotype. Therefore, a better understanding of the functional interaction of epigenetic modifiers with EMT-TFs, their specificity in the EMT and MET processes as well as their specificity for certain tumor types may lead to the identification of new therapeutic targets for preventing metastasis or metastatic outgrowth.

Epigenetic Writers {#s1_2}
------------------

Epigenetic modifiers can be largely classified into the categories of "epigenetic writers", "epigenetic readers" and "epigenetic erasers". Proteins that catalyze a specific histone modification are referred to as "epigenetic writers". Examples of epigenetic writers include DNA and histone/lysine methyltransferases (HMT/KMT), histone/lysine acetyltransferases (HAT/KAT), arginine methyltransferases (PRMT), ubiquitin ligases, etc. As indicated, the EMT transcriptional program is controlled both by DNA methylation \[[@R26]\] and post-translational histone modifications \[[@R27]\].

In mammalian cells, DNA is methylated at the cytosine residues of CpG dinucleotides and is commonly associated with gene repression and heterochromatin formation \[[@R28]\]. In cancer cells, the genome is globally hypomethylated whereas CpG islands are frequently hypermethylated, resulting in reduced expression of tumor suppressor genes \[[@R29]\]. For example, the *CDH1* gene encoding E-cadherin is frequently hypermethylated in breast cancer cell lines exhibiting an EMT-like phenotype \[[@R30]\] and is also shown to be methylated along with several other genes silenced in basal-like breast cancers \[[@R31]\]. In addition to methylation of cytosine, subsequent hydroxylation of 5mC to 5-hydroxymethyl-cytosine (5hmC) and further oxidation to non-methylated cytosine by the Ten-Eleven Translocation (TET) family of methylcytosine dioxygenases plays a tumor suppressor function in many types of cancers \[[@R32],[@R33],[@R34]\]. Notably, TET1 is frequently down-regulated in breast and prostate cancer in cell lines and xenograft models and its downregulation is associated with overall poorer patient survival \[[@R32]\]. This effect appears to be at least partially due to a TET1-dependent demethylation and activation of the Tissue Inhibitor of Metalloproteinase (TIMP)-2 and 3 genes, which are established suppressors of the EMT phenotype. Thus, alterations in both 5mC and 5hmC caused by mutation or repression of the TET proteins may play a role in promoting EMT in solid malignancies. Recently, a role for the TET proteins in metastasis has been shown by demonstrating that the microRNA-22 (miR-22) exerts its prometastatic effects by directly targeting TET proteins \[[@R35]\]. In this way, downregulation of the TET proteins prevents demethylation of the miR-200 gene, which targets the mRNAs for established regulators of the EMT program such as the EMT-TF ZEB1, TGFβ1 and the polycomb protein BMI1, thereby potently antagonizing activation of an EMT program and metastasis.

*Histone Acetyltransferases (HATs)* -- An important and well-studied modification responsible for making chromatin accessible to transcription factors is histone acetylation \[[@R36]\]. Histone acetyltransferases (also referred to as lysine acetyltransferases, KATs) such as GCN5 (KAT2A), P/CAF (KAT2B), p300 (KAT3B) and CBP (KAT3A) transfer acetyl groups to the amino group of lysine side chains of histones, thereby altering the charge of the histone, relaxing the chromatin and making it more accessible to transcription factors \[[@R37]\]. One important HAT, p300, affects the regulation of Snail and ZEB1 in colon cancer, thereby contributing to EMT and tumor progression \[[@R38]\]. A different study reported that the absence of p300 promotes EMT in the HCT116 colorectal cancer cell line \[[@R39]\]. Other HATs such as the human homolog of *males absent on the first* (hMOF/KAT8) as well as the Steroid Receptor Coactivators-1 and -3 (SRC1/NCOA1 and SRC3/NCOA3) have been shown to play tumor and metastasis suppressor and activator roles, respectively \[[@R40],[@R41],[@R42],[@R43],[@R44]\]. However, future studies are needed to address whether and how these or other HATs regulate EMT.

*Histone Methyltransferases (HMTs)* -- Methyltransferases transfer methyl groups to the lysine or arginine residues of histones. They are classified into lysine (KMT) or arginine methyltransferases (PRMT) depending on the substrate residue for methylation. SET (*Su(var) 3-9*, *Enhancer of Zeste* and *Trithorax*) domain containing enzymes such as G9a, SUV39H1/H2, EZH1/2 and others, transfer one to three methyl groups to lysine residues on histones \[[@R45],[@R14]\]. Expressed genes typically display "active" methylation marks such as H3K4me3, H3K36me3 and H3K79me3, while transcriptionally silenced genes generally exhibit "repressive" marks such as H3K27me3, H3K9me2 and H3K9me3. Upon hypoxia, mesenchymal genes are marked with H3K4me3 by WDR5, part of MLL and SET1 HMT complex \[[@R46]\]. The Polycomb Repressor Complex-2 (PRC2), which contains the methyltransferase Enhancer of Zeste Homolog-2 (EZH2) in complex with Suppressor of Zeste-12 (SUZ12) and Embryonic Ectoderm Development (EED) \[[@R47]\], plays a key role in transcriptional silencing by mediating H3K27me3 \[[@R48]\]. The role of PRC2 in tumorigenesis and EMT has been well characterized and its interplay with EMT-TFs is described in more detail below.

*Histone Ubiquitin Ligases* -- Ubiquitination involves the attachment of one or more 76 amino acid ubiquitin moieties to the side chain of a lysine in a process involving the sequential function of three enzymes: E1 ubiquitin-activating, E2 ubiquitin-conjugating and E3 ubiquitin-ligase enzymes \[[@R49]\]. While polyubiquitination via lysine 48 of ubiquitin frequently targets proteins for degradation via the 26S proteasome, monoubiquitination does not usually target proteins for degradation, but rather functions like other post-translational modifications to serve as a mark for recognition by other proteins or directly alter protein structure or function. In the case of chromatin, both histones H2A and H2B can be monoubiquitinated in mammals at Lys-119 (H2Aub1) or Lys-120 (H2Bub1), respectively. H2Bub1 is generally associated with euchromatin and transcriptional elongation \[[@R50],[@R51],[@R52]\], whereas H2Aub1 is localized to regions of heterochromatin and prevents transcriptional elongation \[[@R53],[@R54]\]. H2B is monoubiquitinated by the obligate RNF20/40 heterodimer in a complex with the ubiquitin conjugating enzyme UBE2A (human homolog of yeast Rad6A) \[[@R55]\]. While decreased H2Bub1 levels are associated with increased invasiveness and tumor progression, its role in controlling EMT has not been described yet \[[@R56],[@R57],[@R58],[@R89]\]. In contrast, components of the Polycomb Repressor Complex-1 (PRC1), which ubiquitinates H2A have been shown to promote EMT by upregulating Snail via modulation of PI3K/Akt/GSK-3β signaling \[[@R59]\] as well as targeting other important EMT transcription factors such as Twist1 and ZEB1 \[[@R60],[@R61]\].

Epigenetic Readers {#s1_3}
------------------

Once the chromatin has been marked with specific post-translational histone modifications, the regulatory output in most cases is achieved by the recognition of those marks by epigenetic readers. These chromatin regulators possess specialized domains that recognize and bind to various histone modifications and control DNA-associated functions by recruiting additional regulatory proteins and/or by directly affecting chromatin structure \[[@R62]\].

*Bromodomains* -- Bromodomain-containing proteins recognize acetylated lysine residues \[[@R63],[@R64]\]. One particularly noteworthy subclass of bromodomain proteins is the BET (Bromodomain and Extra Terminal) family of proteins which contain two tandem bromodomains and an Extraterminal domain (ET) \[[@R65]\]. This family consists of BRD2, 3, and 4 as well as the testis-specific BRDT protein and is implicated in transcriptional regulation by binding to chromatin via the bromodomains \[[@R66]\]. In addition to its established role in promoting leukemiogenesis by MLL translocation products \[[@R67]\] and its fusion with NUT in NUT midline carcinoma \[[@R68],[@R69],[@R70]\], BRD4 was shown to suppress an EMT phenotype in mammary epithelial cells \[[@R71]\]. However, additional studies are necessary to further characterize the function and molecular mechanisms of BRD4 and other BET domain proteins in EMT during tumor progression and metastasis. Notably BET domain protein function can be inhibited by small molecule inhibitors such as JQ1 which specifically binds to the bromodomains within BET proteins such as BRD4 and prevents binding to acetylated chromatin \[[@R72]\]. Inhibition of BRD4 has been shown to have a positive effect on MYC-dependent tumor cells \[[@R73],[@R74]\]. However, given a potential EMT suppressor function of BRD4, the potential effects of JQ1 treatment on breast cancer cell phenotype need to be clarified.

*Recognition of Methylated Lysine Residues* -- Analogous to the recognition of acetylated lysine residues by bromodomains, a number of different domains have been identified which recognize methylated lysine residues including Chromatin organization modifier (chromo-), TUDOR, Plant Homeodomain (PHD) and Malignant Brain Tumor (MBT) domains \[[@R75]\]. SFMBT1, a MBT domain containing protein, whose expression has been associated with bad prognosis, forms a complex with the demethylase LSD1 and is recruited to epithelial genes via interaction with SNAI1 to promote gene repression by demethylating H3K4me2 \[[@R76]\]. Within the chromodomain family of proteins there are three sub-families: the heterochromatin protein (HP1)/chromobox (CBX) proteins, the chromodomain helicase DNA binding domain (CHD) subfamily and the chromo barrel domain family \[[@R77]\]. CBX proteins are components of the PRC1 complex which recognizes H3K27me3 to promote H2Aub1 and transcriptional repression at PRC2 targets \[[@R78],[@R79]\]. CBX4 mediates sumoylation of Smad-interacting protein 1 (SIP1), which along with ZEB2, is involved in *CDH1* repression and EMT \[[@R80],[@R81]\]. Another member, MPP8 (M-phase phosphoprotein 8) recognizes H3K9 methylation on chromatin and interacts with HMTases GLP and ESET as well as the DNA methyltransferase DNMT3A. MPP8 in turn functions to repress *CDH1* expression thereby promoting EMT \[[@R82]\].

*Chromatin Remodeling Proteins and Histone Chaperones* -- The regulation of chromatin organization and structure requires both the ATP-dependent activity of chromatin remodeling proteins as well as the ATP-independent functions of histone chaperones \[[@R83],[@R84]\]. One component of the Swi/Snf family of ATP-dependent chromatin remodeling proteins BRG1 was found to be mutated in various human tumor cell lines \[[@R85]\] and appears to function with β-catenin at TCF target gene promoters to facilitate Wnt/β-catenin-regulated gene transcription in colon carcinoma cells \[[@R86]\]. Importantly, BRG1 also interacts directly with the EMT-TF ZEB1 to repress *CDH1* expression and promote EMT \[[@R87]\]. In contrast, Metastasis-associated gene 3 (MTA3), part of the ATP-dependent NuRD/Mi-2/CHD remodeling complex was shown to suppress EMT by directly repressing *SNAI1* expression \[[@R88]\]. Although the activity of histone chaperones has not yet been linked to EMT, our recent data identified decreased expression of the human *Suppressor of Ty Homologue-6* (SUPT6H) during breast cancer progression which was associated with decreased H2Bub1 levels, a loss of estrogen responsiveness and a shift from a luminal epithelial to myoepithelial phenotype \[[@R89]\]. Another histone chaperone complex referred to as Facilitates Chromatin Transcription (FACT) has been implicated in tumorigenesis \[[@R90]\] and DNA repair \[[@R91]\]. Interestingly, an analysis of gene expression data from the Cancer Cell Line Encyclopedia \[[@R92]\] suggest that higher expression of the FACT subunit, Suppressor of Ty Homolog 16 (SUPT16H) is more closely correlated with expression of the epithelial markers CDH1, CRB3, PKP3 and CDH3, and inversely correlated with the expression of the mesenchymal markers AXL, FN1, SNAI2, VIM, CDH2, TWIST1 and ZEB1 (Figure [2](#F2){ref-type="fig"}). Thus, whether and how FACT activity is correlated with an EMT phenotype may be of particular relevance for the application of molecules targeting FACT activity. Future studies will be necessary to determine whether and how SUPT6H, SSRP1, SUPT16H and other histone chaperones promote an EMT phenotype.

![SUPT16H, FACT subunit correlates with the epithelial phenotype in human intestinal cell lines\
Analysis using data from Cancer Cell Line Encyclopedia indicates increased expression of epithelial markers for SUPT16H and decreased expression of mesenchymal markers in intestinal cell lines.](oncotarget-05-2016-g002){#F2}

Epigenetic Erasers {#s1_4}
------------------

In contrast to the notion of epigenetic inheritance, most epigenetic modifications, including extremely stable modifications such as DNA methylation, are highly dynamic and can be added or removed from genes within minutes, frequently in a cyclic fashion \[[@R93],[@R94],[@R95]\]. After the initial activation or repression of a gene has been achieved, cellular and transcriptional plasticity is maintained by the reversibility of the epigenetic status of the target genes. In order to achieve this, most histone modifications also have specific enzymes that catalyze their removal. This class of proteins is broadly referred to as "epigenetic erasers" and exerts an equally important function as writers. If the signal is not stopped in a timely manner, the results can lead to defects in transcription and DNA repair ultimately promoting tumorigenesis of tumor progression \[[@R96]\].

*Histone Deacetylases (HDACs)* -- The acetyl groups added by HATs are removed by HDACs in a highly regulated fashion which generally leads to chromatin compaction and transcriptional repression. Notably, HDAC1 was found to be important for TGFβ1-induced EMT \[[@R97]\] and its inhibition suppressed TGFβ1-induced EMT \[[@R98]\]. HDAC3 also interacts with WDR5, a core component of the histone methyltransferase complex responsible for H3K4 methylation and induced hypoxia-mediated EMT by regulating acetylation and methylation patterns on EMT genes \[[@R46]\]. Furthermore, the NAD^+^-dependent histone deacetylase SIRT1 was shown to cooperate with ZEB1 to silence *CDH1* expression by deacetylating its promoter \[[@R99]\].

*Histone Demethylases* -- Finally, histone demethylases revert the effect of HMTs by removing the methylation marks on histones. The first histone demethylase identified was Lysine-Specific Demethylase-1 (LSD1 or KDM1A) \[[@R100]\], which removes mono- and di- methyl groups from H3K4. During EMT, SNAI1 recruits LSD1 to epithelial gene promoters and represses transcription by removal of dimethylation from H3K4 \[[@R101],[@R102],[@R103]\]. Two other demethylases belonging to the Jumonji-domain family, KDM6B (JMJD3) which removes H3K27me3 and KDM4B (JMJD2B), responsible for demethylation of H3K9me3 and H3K36me3, were recently shown to promote EMT as well \[[@R104],[@R105]\].

*Histone Deubiquitinases (DUBs)* -- As with essentially all other post-translational modifications, the ubiquitin moiety from histones can also be removed in order to reverse the effects of ubiquitination. One example is Ubiquitin-Specific Protease-22 (USP22) which deubiquitylates histone H2B \[[@R106]\] and was found to regulate BMI1-mediated INK4a/ARF and Akt signaling \[[@R107]\]. Consistently, USP22 is upregulated in tumors with a stem cell-like phenotype from patients exhibiting overall poorer survival \[[@R106],[@R108],[@R109]\]. Although many lines of research suggest that the positive and negative regulation of H2Bub1 could be associated with a tumor stem cell-like phenotype and EMT, further work will be needed to address this. The ubiquitination of H2A was reported to be reversed by a number of different DUBs including USP3 \[[@R110]\]. Notably, USP3 depletion induces scattering of A549 epithelial lung cancer cells, possibly reflecting a more mesenchymal cellular phenotype \[[@R111]\]. However, how and whether H2A deubiquitination is involved in controlling EMT still needs to be resolved.

Epigenetic Regulation of EMT-Inducing Transcription Factors {#s1_5}
-----------------------------------------------------------

The cellular plasticity which allows the inter-conversion between epithelial and mesenchymal phenotypes via EMT and MET requires a complex network of interactions between different EMT-TFs, ubiquitous TFs and the epigenetic regulators described above. Herein, both the expression and the activity of EMT-TFs are controlled at an epigenetic level. The connection between loss of E-cadherin and tumor progression has been well established \[[@R112]\], and studies have highlighted the epigenetic regulation of the *CDH1* gene encoding E-cadherin to be instrumental for cancer cell metastasis \[[@R113]\]. *CDH1* expression is regulated by EMT-TFs including the Snail transcription factor family members Snail (SNAI1) and Slug (SNAI2) \[[@R114]\]. Research has shown that Snail recruits several chromatin modifying enzymes, such as LSD1, G9a, Suv39H1, HDAC1/2 and PRC2, to the *CDH1* promoter for transcriptional repression \[[@R115],[@R116],[@R117],[@R118]\]. Figure [3](#F3){ref-type="fig"} and Table [1](#T1){ref-type="table"} list the described interactions of EMT-inducing factors with various epigenetic factors to transcriptionally repress epithelial genes during EMT.

![EMT-TFs interact with epigenetic regulators to repress epithelial genes\
EMT inducing factors activate the EMT-TFs which in turn interact with epigenetic regulators to repress the expression of epithelial genes. PRC2, polycomb repressive complex 2; DNMT1, DNA methyltransferase 1; HDAC, histone deacetylase; CtBP, C-terminal binding protein; BMI1, B lymphoma Mo-MLV insertion region 1; SET, Su(var) 3-9, Enhancer of Zeste and Trithorax](oncotarget-05-2016-g003){#F3}

###### Epigenetic factors involved in EMT

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Transcription factor   Molecular function                                                       Modifications          EMT regulation                                                           Refs
  ---------------------- ------------------------------------------------------------------------ ---------------------- ------------------------------------------------------------------------ -------------------------------------
  HDACs                  Histone deacetylases                                                     H3K ac                 WDR5 controls H3K4me3 on EMT genes;\                                     \[[@R46],[@R133],[@R134]\]
                                                                                                                         CDH1 repression with Snail & Twist1                                      

  EZH2                   Polycomb protein complex 2 (PRC2) component, histone methyltransferase   H3K27me3               Activated by SOX4; EMT epithelial gene repression; often overexpressed   \[[@R121],[@R135]\]

  SUZ12                  Polycomb protein complex 2 (PRC2) component                              H3K27me3 with EZH2     Often overexpressed                                                      \[[@R136]\]

  BMI1                   Polycomb protein complex 1 (PRC1) component; gene silencing              H2Aub1                 Upregulated during EMT;\                                                 \[[@R137],[@R138],[@R139],[@R140]\]
                                                                                                                         EMT gene repression with Snail & Twist1                                  

  SUV39H1                Histone methyltransferase                                                H3K9me3                SNAI1 mediated CDH1 repression                                           \[[@R115]\]

  G9a                    Histone methyltransferase                                                H3K9me2                SNAI1 mediated CDH1 repression                                           \[[@R116]\]

  LSD1                   Histone demethylase                                                      H3K4me1/2; H3K9me1/2   SNAI1 mediated repression                                                \[[@R100],[@R141],[@R142]\]

  KDM6B (JMJD3)          Histone demethylase                                                      H3K27me3               SNAI1 mediated repression                                                \[[@R104]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*SOX4 -- An Important Upstream Regulator of the EMT Program --* SOX4 is a member of the Sox (SRY-related HMG-box) family of transcription factors and is frequently upregulated in various cancer types \[[@R120]\]. A recent study demonstrated that SOX4 acts early in the induction of the EMT pathway \[[@R121]\]. Upon TGFβ1 induction, SOX4 expression is increased, thereby transcriptionally activating *EZH2* expression, which in turn increases H3K27me3 at specific genes in order to promote EMT. In concordance with this, depletion of either the transcription factor SOX4 or its epigenetic regulatory partner EZH2 similarly prevented TGFβ-induced EMT in the murine mammary epithelial cell line NMuMG. Similarly, SOX4 overexpression induced EMT via modulation of Ezh2-mediated H3K27me3 marks on several EMT genes. Together these results strongly implicate SOX4 as a critical upstream regulator of the EMT modulators that carries out its function via epigenetic mechanisms involving EZH2.

SUV39H1 (*Suppressor of Variegation 3-9* Homolog 1), is a key HMT responsible for trimethylation of H3K9. H3K9me3, like H3K27me3, is a histone modification associated with gene repression. Recently, it was shown that SUV39H1 and SNAI1 were concomitantly upregulated in MCF10A cells following TGFβ1 induction. These factors have been shown to interact with each other establishing a repressed state of the *CDH1* promoter by increasing the levels of H3K9me3 \[[@R115]\].

ZEB1 and ZEB2 are key factors regulating CDH1 expression and their connection with EMT and metastasis of cancer cells has been well established \[[@R121]\]. In a recent study it was shown that the ZEB1 promoter may exist in a poised state containing both marks of activation (H3K4me3) and repression (H3K27me3) \[[@R122]\]. In epithelial cells, ZEB1 is not expressed due to the bivalent marks on its promoter, whereas TGFβ1-mediated EMT induction resulted in removal of H3K27me3 from the ZEB1 promoter thereby facilitating its expression.

Similarly, removal of H3K27me3 by KDM6B was also shown to be essential for the induction of *SNAI1* expression during TGFβ1-induced EMT \[[@R104]\].

Apart from histone methylation, histone acetylation on the genes encoding EMT transcription factors has also been investigated. In this regard, it was previously shown that histone deacetylases (HDACs) modulated the chromatin state upon stimulus of extracellular signals like hypoxia \[[@R46]\]. Upon hypoxia, a well-described inducer of cancer cell aggressiveness and EMT, HDAC3 was recruited to epithelial genes such as *CDH1* leading to decreased H3K4ac, a subsequent increase in H3K4me2 and H3K27me3, and ultimately gene repression. On the other hand, mesenchymal genes such as Vimentin showed decreased H3K4ac, increased H3K4me2 but decreased H3K27me3. Here, HDAC3 interacted with WDR5, leading to methylation of H3K4 in hypoxic cells.

In non-small cell lung cancer cell lines it was also shown that ZEB1 downregulated its target genes, e.g. EpCAM (epithelial cell adhesion molecule) by globally decreasing H3K27ac marks on these genes \[[@R123]\]. These findings are critical in understanding that the epigenetic regulation occurs relatively upstream of these markers or transcription factors, which may lead to the evaluation of these upstream EMT regulators as potential targets in anti-metastatic therapy. Figure [4](#F4){ref-type="fig"} demonstrates the cascade of epigenetic events that control the transcriptional regulation of EMT transcription factors in response to EMT stimuli. The EMT TFs further function to directly regulate the transcription of epithelial and mesenchymal genes together with epigenetic coregulators.

![Signaling activators induce transcription of EMT-TFs which in turn regulate histone modifications on target genes\
Upon inducing signal, activating histone modifications on the genes of EMT-TFs promote transcription. EMT-TFs then interact with epigenetic regulators to mark the target genes for activation or repression.](oncotarget-05-2016-g004){#F4}

Perspectives {#s1_6}
------------

Cancer cells exploit epigenetic regulatory mechanisms for increased survival and resistance to apoptosis. It is now well established that chromatin regulation is an important determinant in controlling EMT, MET and cancer progression \[[@R119]\]. As the role of epigenetics in cancer becomes more apparent, we envisage that new strategies for the treatment of cancer will be developed that specifically focus on epigenetic dysregulation found in cancer cells. Targeting the molecular mechanisms for the methylation or acetylation of histones as shown partly in hematological malignancies could be a potential strategy of preventing EMT from occurring in solid tumors, thus interfering with local and systemic tissue infiltration. Several studies have now established various inhibitors targeting the key enzymes regulating the histone modifications that could potentially prevent the onset of EMT and tumor progression. For example, histone deacetylase inhibitors have been characterized that work on various HDACs, thereby maintaining the fine balance between HATs and HDACs \[[@R124]\]. EZH2, a well-known HMT implicated in regulating EMT by affecting H3K27me3 on EMT target genes, can be inhibited using the newly developed inhibitor EPZ005687. As a proof of principle, EPZ005687 was found to reduce H3K27me3 in lymphoma cells and render them more susceptible to induction of apoptosis \[[@R125]\]. Additionally, histone demethylases such as KDM6B/JMJD3 contribute to EMT by removing repressive marks from genes encoding EMT-TFs. A specific inhibitor for these demethylases such as the newly developed KDM6A/B inhibitor GSK-J4 was able to prevent the upregulation of EMT genes like SNAI1 \[[@R126]\]. JMJD3 has been shown to activate INK4a/ARF locus by its demethylase activity \[[@R127]\]. Hence, inhibition of JMJD3 might provide a viable approach for limiting epigenetic plasticity during tumor progression.

An exception to the family of SET domain containing methyltransferases is DOT1L which is responsible for H3K79 methylation. In AML with recurrent mixed lineage leukemia (MLL) gene translocation resulting in aggressive leukemias, DOT1L is aberrantly recruited to MLL target genes via interaction with the MLL translocation product where the expression of these genes also requires DOT1L histone methyltransferase activity \[[@R128]\]. In addition, DOT1L was shown to play a central role in the regulation of Wnt/β-catenin-regulated gene transcription \[[@R129],[@R130]\]. Given the importance of the Wnt pathway in controlling EMT, it is possible that targeting DOT1L, for example via the small molecule inhibitor EPZ004777 which prevents H3K79 methylation on leukemic genes and selectively targets the cell carrying the MLL translocation \[[@R131]\], may represent a potential therapeutic target for anti-EMT therapy in specific cases where Wnt signaling plays a central role.

As we continue to elucidate the molecular circuits of epithelial-mesenchymal plasticity and its consequences for different aspects of tumor progression, we are obtaining a more precise view of the local and global epigenetic alterations in cancer cells undergoing EMT. We are just now beginning to understand how those changes induce EMT and MET or function to maintain epithelial and mesenchymal phenotypes. In sharp contrast to transcription factors, epigenetic regulators are amenable to targeting by small molecule inhibitors. Therefore, specific approaches targeting them may yield newer and better treatments based on characterized molecular mechanisms. It remains to be seen whether single inhibitors of EMT regulators will demonstrate clinical utility with regard to cancer invasion and metastasis prevention. A better understanding of the epigenetic mechanisms controlling the EMT and MET processes during distinct steps of metastasis formation together with the development of new, highly specific small molecule inhibitors will be essential for testing the feasibility of this approach and taking the next step toward individualized epigenetic tumor therapy.
